劉德果 趙姣 蘇藝峰 陳其華 胡金輝 向時(shí)竹 林夢(mèng)姣

〔摘要〕 目的 基于數(shù)據(jù)挖掘研究現(xiàn)代湖湘男科流派代表醫(yī)家譚新華、賀菊喬、陳其華治療激素難治性前列腺癌（hormone refractory prostate cancer， HRPC）的用藥規(guī)律。方法 收集2012年5月至2020年8月現(xiàn)代湖湘男科流派醫(yī)家譚新華、賀菊喬、陳其華于湖南中醫(yī)藥大學(xué)第一附屬醫(yī)院國(guó)醫(yī)堂專家門(mén)診治療HRPC的處方，采用中醫(yī)傳承輔助平臺(tái)軟件（V 2.50）對(duì)上述處方進(jìn)行描述性分析、關(guān)聯(lián)規(guī)則分析、復(fù)雜系統(tǒng)熵聚類分析。結(jié)果 本研究共納入HRPC治療處方241首，涉及藥物99味，頻次>100次的藥物共14味，前5位依次為黃芪、甘草、三棱、莪術(shù)、熟地黃。藥物四氣前3位分別為溫、寒、平;藥物五味前3位分別為甘、辛、苦;藥物歸經(jīng)前3位分別為腎、脾、肝。獲得治療HRPC藥物組合28條;經(jīng)復(fù)雜系統(tǒng)熵聚類分析后，獲得7個(gè)核心藥對(duì)及4個(gè)新藥物組合。結(jié)論 “腎虛血瘀”是HRPC發(fā)病的主要病機(jī)，現(xiàn)代湖湘男科流派醫(yī)家治療HRPC遣方用藥側(cè)重于益腎溫陽(yáng)，活血化瘀，可為中醫(yī)臨床治療HRPC提供用藥參考。

〔關(guān)鍵詞〕 前列腺癌;激素難治性前列腺癌;數(shù)據(jù)挖掘;用藥規(guī)律;男科;醫(yī)家

〔中圖分類號(hào)〕R277.5? ? ? ?〔文獻(xiàn)標(biāo)志碼〕A? ? ? ?〔文章編號(hào)〕doi：10.3969/j.issn.1674-070X.2021.05.014

Research on the Drug Rule of Modern Huxiang Andrology School in the Treatment of

Hormone-refractory Prostate Cancer Based on Data Mining

LIU Deguo1，2， ZHAO Jiao1， SU Yifeng1， CHEN Qihua2*， HU Jinhui2， XIANG Shizhu1， LIN Mengjiao1

（1. Hunan University of Chinese Medicine， Changsha， Hunan 410008， China; 2. The First Affiliated Hospital of Hunan University of Chinese Medicine， Changsha， Hunan 410208， China）

〔Abstract〕 Objective Based on data mining to study the medication rules of modern Huxiang andrology school representatives Tan Xinhua， He Juqiao， Chen Qihua， etc. in the treatment of hormone refractory prostate cancer （HRPC）. Methods From May 2012 to August 2020， doctors Tan Xinhua， He Juqiao， and Chen Qihua from the modern Huxiang andrology school were collected from the expert clinic of the Traditional Chinese Medicine Hall of the First Affiliated Hospital of Hunan University of Chinese Medicine. The prescriptions for HRPC were collected， and the traditional Chinese medicine inheritance auxiliary platform software （V 2.50） was used to perform descriptive analysis， association rule analysis， and complex system entropy cluster analysis on the above prescriptions. Results A total of 241 prescriptions for HRPC were included in this study， involving 99 drugs， and 14 drugs with a frequency of more than 100 times. The top 5 were Huangqi （Astragali Radix）， Gancao （Glycyrrhizae Radix Et Rhizoma）， Sanleng （Sparganii Rhizoma）， Ezhu （Curcumae Rhizoma）， Shudihuang （Rehmanniae Radix Praeparata）. The top 3 of the four Qi of the drug were warm， cold， and flat; the top 3 of the five flavors of the drug were sweet， pungent， and bitter; the top 3 of the channels of the drug were kidney， spleen， and liver. 28 drug combinations for the treatment of HRPC were obtained through the association rule analysis; after complex system entropy cluster analysis， 7 core drug pairs and 4 new drug combinations were obtained. Conclusion "Kidney deficiency and blood stasis" is the main pathogenesis of the onset of HRPC. Modern Huxiang andrology school doctors used medicines to treat HRPC with a focus on invigorating the kidney and warming Yang， promoting blood circulation and removing blood stasis drugs， which can provide a reference for the clinical treatment of HRPC in traditional Chinese medicine.